Amarin Corp Plcuk (AMRN) Receivables - Net (2013 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Receivables - Net of $108.4 million for Q2 2026, down 19.18% year-over-year from $134.1 million in Q2 2025, and down 11.92% quarter-over-quarter from $123.0 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Receivables - Net (2013 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Receivables - Net for 14 consecutive years, with $108.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Receivables - Net fell 19.18% year-over-year to $108.4 million; the TTM figure through Jun 2026 stood at $108.4 million (down 19.18% YoY), while the FY2025 annual figure was $145.0 million, up 8.95% from the prior year.
- Receivables - Net retreated to $108.4 million in Q2 2026 per AMRN's latest filing, from $123.0 million in the prior quarter.
- Across five years, Receivables - Net topped out at $217.8 million in Q1 2022 and bottomed at $108.4 million in Q2 2026.
- Historically, Receivables - Net has averaged $152.9 million across 5 years, with a median of $147.8 million in 2024.
- Annual changes were most pronounced in 2022 — Receivables - Net fell 28.72% — and 2025, when it advanced 8.95%.
- Amarin Corp Plc\Uk's Receivables - Net stood at $187.4 million in 2022, then declined by 14.26% to $160.7 million in 2023, then retreated by 17.19% to $133.1 million in 2024, then increased by 8.95% to $145.0 million in 2025, then retreated by 25.25% to $108.4 million in 2026.
- Business Quant data shows AMRN's Receivables - Net at $108.4 million in Q2 2026, $123.0 million in Q1 2026, and $145.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.49 Bn | 632.73 Bn | 17.26 Bn |
| 2 | AbbVie | 470.91 Bn | 464.34 Bn | 12.70 Bn |
| 3 | Merck | 379.63 Bn | 372.49 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.14 Bn | 295.45 Bn | 11.24 Bn |
| 5 | Astrazeneca | 258.40 Bn | 253.50 Bn | 12.86 Bn |
| 6 | Amgen | 237.10 Bn | 223.11 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.02 Bn | 179.84 Bn | 6.22 Bn |
| 8 | Pfizer | 161.60 Bn | 149.90 Bn | 10.94 Bn |
| 9 | Gsk | 105.86 Bn | 101.70 Bn | 8.24 Bn |
| 10 | Amarin Corp Plcuk | 5.89 Bn | 5.57 Bn | 14.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.38 Mn |
| Jun 30, 2026 | 108.38 Mn |
| Mar 31, 2026 | 123.04 Mn |
| Mar 31, 2026 | 123.04 Mn |
| Dec 31, 2025 | 144.98 Mn |
| Dec 31, 2025 | 144.98 Mn |
| Sep 30, 2025 | 141.30 Mn |
| Sep 30, 2025 | 141.30 Mn |
| Jun 30, 2025 | 134.10 Mn |
| Jun 30, 2025 | 134.10 Mn |
| Mar 31, 2025 | 118.68 Mn |
| Mar 31, 2025 | 118.68 Mn |
| Dec 31, 2024 | 133.07 Mn |
| Dec 31, 2024 | 133.07 Mn |
| Sep 30, 2024 | 130.25 Mn |
| Sep 30, 2024 | 130.25 Mn |
| Jun 30, 2024 | 150.63 Mn |
| Jun 30, 2024 | 150.63 Mn |
| Mar 31, 2024 | 137.03 Mn |
| Mar 31, 2024 | 137.03 Mn |